All reviews of published articles are made public. This includes manuscript files, peer review comments, author rebuttals and revised materials. Note: This was optional for articles submitted before 13 February 2023.
Peer reviewers are encouraged (but not required) to provide their names to the authors when submitting their peer review. If they agree to provide their name, then their personal profile page will reflect a public acknowledgment that they performed a review (even if the article is rejected). If the article is accepted, then reviewers who provided their name will be associated with the article itself.
Thank you for addressing all the reviewers comments. At this time, this version of your article does not require further changes,
no comment
no comment
no comment
no comment
This is a well-designed, well-executed, and well-written research paper.
However, there are some reviewer comments that need to be revised, please make these changes to improve the quality of your article.
It is a clear, concise, and well-written manuscript. However, the authors need to incorporate and revise certain aspects of their manuscript:
• Lines 79-81: It is suggested that reference 1 be replaced with the most recent one. “The global diabetes prevalence in 20-79-year old in 2021 was estimated to be 10.5% (536.6 million people), rising to 12.2% (783.2 million) in 2045” by Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6. Erratum in: Diabetes Res Clin Pract. 2023 Oct;204:110945. doi: 10.1016/j.diabres.2023.110945. PMID: 34879977; PMCID: PMC11057359.
• Lines 99-100: A brief description of CVAI is needed.
• Lines104-106: the aims of this study need to be clarified.
• Lines 111-112: Most recent publications used type 2 diabetes (T2D) instead of type 2 diabetes mellitus (T2DM).
• Lines 136-137: A reference for the “Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation” is needed
Exclusion criteria
• Lines 113-117: Did you exclude diabetic patients who have hypertension and are taking antihypertensive drugs, which might increase serum uric acid, such as thiazide-type diuretics, β blockers, ACE, and ARBs?
• Line 195: It is advisable to mention that age and estimated glomerular filtration rate (eGFR) had a significant negative correlation with hyperuricemia.
• Lines 239-240: Can you please mention the cutoff point for the basic model and +CVAI in Table 4
• It is advisable to add a paragraph about hypertension and HUA, especially the medication used for the treatment of hypertension
No comment
No comment
No comment
In Figure 3, instead of HDL, there should be HDL-C and instead of LDL - LDL-C.
I do not see the need for the authors to explain the abbreviations that have already been explained once constantly; this mainly concerns laboratory parameters and the studied index (CVAI). I suggest the authors read the papers in this regard and catch these errors.
I believe that as a risk factor associated with HUA, the authors should add urolithiasis in the introduction. Studies are showing the relationship between uric acid-metabolic syndrome-HUA.
I also believe that the authors should look at the articles on HUA ghrelin and adiponectin - because their results are interesting in the context of metabolic syndrome and they could refer to this in the discussion.
All text and materials provided via this peer-review history page are made available under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.